TransMedics Group, Inc. (NASDAQ:TMDX) Position Increased by IFP Advisors Inc

IFP Advisors Inc increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 732.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,783 shares of the company’s stock after acquiring an additional 5,968 shares during the period. IFP Advisors Inc’s holdings in TransMedics Group were worth $423,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Arcadia Investment Management Corp MI acquired a new stake in shares of TransMedics Group in the fourth quarter valued at about $72,000. Handelsbanken Fonder AB lifted its stake in TransMedics Group by 27.2% during the fourth quarter. Handelsbanken Fonder AB now owns 81,900 shares of the company’s stock worth $5,106,000 after purchasing an additional 17,500 shares during the period. Global Retirement Partners LLC lifted its stake in TransMedics Group by 4,132.5% during the fourth quarter. Global Retirement Partners LLC now owns 3,259 shares of the company’s stock worth $203,000 after purchasing an additional 3,182 shares during the period. Peregrine Capital Management LLC lifted its stake in TransMedics Group by 64.0% during the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company’s stock worth $4,124,000 after purchasing an additional 25,814 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in shares of TransMedics Group by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 1,373 shares of the company’s stock valued at $86,000 after acquiring an additional 504 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Trading Up 5.8 %

NASDAQ:TMDX opened at $76.32 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a 50-day moving average of $67.81 and a 200-day moving average of $101.20. The company has a market cap of $2.56 billion, a PE ratio of 81.19 and a beta of 2.12. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

Analyst Ratings Changes

Several research firms recently weighed in on TMDX. Piper Sandler dropped their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $122.70.

Insiders Place Their Bets

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.